Listen "The FLAURA Trial: Practice-Changing Results for Patients with EGFR Mutation-Positive NSCLC (BMIC-007)"
Episode Synopsis
Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI therapy (gefitinib or erlotinib) as first line treatment for patients with EGFR mutation-positive NSCLC.
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.